Literature DB >> 29477391

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Patricia M Danzon1, Michael F Drummond2, Adrian Towse3, Mark V Pauly4.   

Abstract

The fourth section of our Special Task Force report focuses on a health plan or payer's technology adoption or reimbursement decision, given the array of technologies, on the basis of their different values and costs. We discuss the role of budgets, thresholds, opportunity costs, and affordability in making decisions. First, we discuss the use of budgets and thresholds in private and public health plans, their interdependence, and connection to opportunity cost. Essentially, each payer should adopt a decision rule about what is good value for money given their budget; consistent use of a cost-per-quality-adjusted life-year threshold will ensure the maximum health gain for the budget. In the United States, different public and private insurance programs could use different thresholds, reflecting the differing generosity of their budgets and implying different levels of access to technologies. In addition, different insurance plans could consider different additional elements to the quality-adjusted life-year metric discussed elsewhere in our Special Task Force report. We then define affordability and discuss approaches to deal with it, including consideration of disinvestment and related adjustment costs, the impact of delaying new technologies, and comparative cost effectiveness of technologies. Over time, the availability of new technologies may increase the amount that populations want to spend on health care. We then discuss potential modifiers to thresholds, including uncertainty about the evidence used in the decision-making process. This article concludes by discussing the application of these concepts in the context of the pluralistic US health care system, as well as the "excess burden" of tax-financed public programs versus private programs.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  budgets; cost-effectiveness; opportunity cost; thresholds

Mesh:

Year:  2018        PMID: 29477391     DOI: 10.1016/j.jval.2017.12.008

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  9 in total

1.  Insurance payment for artificial intelligence technology: Methods used by a stroke artificial intelligence system and strategies to qualify for the new technology add-on payment.

Authors:  Nick M Murray; Phillip Phan; Greg Hager; Andrew Menard; David Chin; Alvin Liu; Ferdinand K Hui
Journal:  Neuroradiol J       Date:  2022-01-06

2.  Assessing potential cures: are there distinctive elements of value beyond health gain?

Authors:  Saskia Hendriks; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2021-03-05       Impact factor: 1.744

Review 3.  Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.

Authors:  Fernanda S Tonin; Ignacio Aznar-Lou; Vasco M Pontinha; Roberto Pontarolo; Fernando Fernandez-Llimos
Journal:  Pharm Pract (Granada)       Date:  2021-02-22

4.  ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2019-10-31

Review 5.  The political economics of cancer drug discovery and pricing.

Authors:  David G Taylor
Journal:  Drug Discov Today       Date:  2020-09-11       Impact factor: 7.851

6.  Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis.

Authors:  T Joseph Mattingly; Julia F Slejko; Eberechukwu Onukwugha; Eleanor M Perfetto; Shyamasundaran Kottilil; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

7.  Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].

Authors:  Charles E Phelps; Darius N Lakdawalla; Anirban Basu; Michael F Drummond; Adrian Towse; Patricia M Danzon
Journal:  Value Health       Date:  2018-02       Impact factor: 5.725

8.  The cost of cancer - A comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe.

Authors:  Max Schlueter; Katie Chan; Romain Lasry; Martin Price
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

Review 9.  Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy.

Authors:  Tanja Fens; Eugène P van Puijenbroek; Maarten J Postma
Journal:  Front Med Technol       Date:  2021-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.